Tumor-derived biomarkers beyond antigen expression enhance efficacy of CD276/B7H3 antibody-drug conjugate in metastatic prostate cancer
Supreet Agarwal(University of Iowa), Kathleen Kelly(National Cancer Institute), Anson T. Ku(National Cancer Institute), Elaine M. Hurt, Clare Hoover(AstraZeneca (Netherlands)), Lawrence D. True(University of Washington Medical Center), Martine P. Roudier(University of Washington), Adam G. Sowalsky(National Cancer Institute), Kerry M. McGowen(National Cancer Institute), Ruth F. Dumpit(Fred Hutch Cancer Center), Ilya S. Senatorov(National Cancer Institute), Joel Bowman(National Cancer Institute), John K. Lee(APLA Health), Peter S. Nelson(Fred Hutch Cancer Center), Brian J. Capaldo(University of Virginia), Ilsa M. Coleman(Fred Hutch Cancer Center), Lei Fang(Jiujiang University), Aian Neil Alilin(National Cancer Institute), Aida Mariani(AstraZeneca (Netherlands)), Michael L. Beshiri(National Cancer Institute), JuanJuan Yin(National Cancer Institute), Eva Corey(University of Washington)
Cited by 1
Related Papers
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
|New England Journal of Medicine|2016|1.6k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k